Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3CNS 3Thoracic 2Plasma cell 1Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Multiple Myeloma 229Lymphoma 30Hematologic Neoplasms 21Recurrence 17Neoplasms 14Neoplasms, Plasma Cell 13Immunoglobulin Light-chain Amyloidosis 13Lymphoma, Non-Hodgkin 12Leukemia, Lymphocytic, Chronic, B-Cell 12Leukemia, Myeloid, Acute 10Lymphoma, Mantle-Cell 9Smoldering Multiple Myeloma 8Prostatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic Syndromes 8Lymphoma, Large B-Cell, Diffuse 8Hodgkin Disease 8Ovarian Neoplasms 6Lung Neoplasms 6Leukemia, Plasma Cell 6Breast Neoplasms 6Waldenstrom Macroglobulinemia 5Melanoma 5Lymphoma, Follicular 5Monoclonal Gammopathy of Undetermined Significance 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4

Interventions

fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × Plasma cell × 30 days × Clear all
NCT05092451 2026-05-06

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
80 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Germ Cell and Embryonal, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡